ArticleGland surgery2022
Clinicopathological features and prognosis of papillary thyroid cancer patients with type 2 diabetes mellitus.
Article in Gland surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Validation of quercetin in the treatment of colon cancer with diabetes via network pharmacology, molecular dynamics simulations, and in vitro experiments.Molecular diversity · 2024Article
- Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.BMC cancer · 2024Article
- The protective role of nutritional antioxidants against oxidative stress in thyroid disorders.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinicopathological characteristics of patients with papillary thyroid carcinoma (PTC) combined with type 2 diabetes mellitus (T2DM) and patients with PTC alone were explored and compared in order to provide a more reasonable treatment plan for the clinical diagnosis and treatment of these patients. Methods: A total of 1,771 patients from January 2017 to December 2019 who underwent PTC surgery for the first time in the west branch of the Fourth Hospital of Hebei Medical University were analyzed retrospectively. Among them, 111 patients had PTC with T2DM (D-T group) and 1,660 patients had PTC alone (PTC group). The differences in general data and clinical characteristics between the D-T group and the PTC group were analyzed. Results: There were statistically significant differences in age, gender, and body mass index (BMI) between the D-T group and PTC group (P<0.05). Multifocality and extra-glandular invasion in the D-T group were significantly higher than the PTC group (P<0.05). In women, the D-T group was older, had a higher BMI, and was more likely to have extra-glandular invasion (P<0.05) than the PTC group. The prognosis of the D-T group was worse than that of the PTC group as determined by 3 well-developed prognostic staging systems, 8th AJCC TNM staging, MAGIS SCORE, AMES staging, and the results were statistically significant (P=0.001, P<0.001, P=0.021). Conclusions: Our study showed that the overall prognosis of PTC patients with T2DM was worse than that of patients with PTC alone. At the same time, especially in patients younger than 55 years of age, multifocal carcinoma and extra-glandular invasion are likely to occur. In addition, female patients with T2DM are more likely to have extra-glandular invasion than male patients. Therefore, for such patients, preoperative evaluation should be fully conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.